Pierre Fabre Drug Patent Portfolio

Pierre Fabre owns 1 orange book drug protected by 2 US patents Given below is the list of Pierre Fabre's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8338489 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas 16 Oct, 2028
Active
US8987262 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas 16 Oct, 2028
Active


Given below is the list of recent legal activities going on the following drug patents of Pierre Fabre.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 28 May, 2024 US8338489
Payment of Maintenance Fee, 8th Year, Large Entity 28 May, 2020 US8338489
Patent Issue Date Used in PTA Calculation 25 Dec, 2012 US8338489
Recordation of Patent Grant Mailed 25 Dec, 2012 US8338489
Issue Notification Mailed 05 Dec, 2012 US8338489
Dispatch to FDC 29 Nov, 2012 US8338489
Application Is Considered Ready for Issue 19 Nov, 2012 US8338489
Issue Fee Payment Received 16 Nov, 2012 US8338489
Issue Fee Payment Verified 16 Nov, 2012 US8338489
Response to Reasons for Allowance 16 Nov, 2012 US8338489
Supplemental Papers - Oath or Declaration 13 Nov, 2012 US8338489
Miscellaneous Incoming Letter 13 Nov, 2012 US8338489
Mail Miscellaneous Communication to Applicant 18 Oct, 2012 US8338489
Miscellaneous Communication to Applicant - No Action Count 11 Oct, 2012 US8338489
Printer Rush- No mailing 11 Oct, 2012 US8338489


Pierre Fabre Drug Patents' Oppositions Filed in EPO

Pierre Fabre drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 09, 2012, by Infectopharm Arzneimittel Und Consilium Gmbh. This opposition was filed on patent number EP08838691A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP08838691A Mar, 2012 Infectopharm Arzneimittel und Consilium GmbH Opposition rejected


Pierre Fabre's Family Patents

Pierre Fabre drugs have patent protection in a total of 32 countries. It's US patent count contributes only to 14.0% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Pierre Fabre Drug List

Given below is the complete list of Pierre Fabre's drugs and the patents protecting them.


1. Hemangeol

Hemangeol is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8338489 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas 16 Oct, 2028
(3 years from now)
Active
US8987262 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas 16 Oct, 2028
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Hemangeol's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List